PSMA PET for the Staging and Management of Hepatocellular Carcinoma
Addition of F18-Piflufolastat PET/CT to Cross-Sectional Imaging for the Staging and Management of Hepatocellular Carcinoma
VA Office of Research and Development
90 participants
Sep 19, 2024
OBSERVATIONAL
Conditions
Summary
This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC). The study aims to determine whether PSMA PET/CT improves diagnostic accuracy for indeterminate liver lesions (LI-RADS 3 and 4), enhances staging precision in treatment-naïve patients, and provides more accurate assessment of treatment response in patients undergoing locoregional therapy (LRT). The goal is to assess how PSMA PET/CT may impact clinical decision-making, staging, and management of HCC across multiple stages of disease.
Eligibility
Inclusion Criteria2
- Adult patients age \>18 years from the VA medical system
- Treatment-naïve patients with HCC with BCLC B or C disease
Exclusion Criteria2
- Patients with renal dysfunction or contrast allergy that precludes contrast enhanced cross sectional imaging
- Patients with presence of active primary malignancy other than HCC and non-melanoma skin cancer in the past 3 years
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07019844